Tumor-Specific Immunotherapy for Patients with High-Risk Melanoma: The Potential Role of mRNA Cancer Vaccines

Since the release of 5-year follow-up data from the Phase IIb KEYNOTE-942 study, in which the mRNA vaccine intismeran autogene is used in combination with pembrolizumab to treat high-risk resected melanoma, the potential of new and more effective immune therapies for solid tumors has been increasingly discussed. In this episode of OncTimes Talk, we hear from a key melanoma specialist at the world's largest center for melanoma research. 

Alexander C. J. van Akkooi, MD, PhD, FRACS, FSSO, Associate Professor of Melanoma Surgical Oncology at the Melanoma Institute Australia, University of Sydney, and the Department of Melanoma Surgical Oncology at Royal Prince Alfred Hospital in Sydney, Australia, talks about the growing range of immunological therapy options for patients with melanoma. He discusses how the newer mRNA cancer vaccines could enhance therapy if mature data fulfil their early promise.